BrightInsight developed the Disease Management Solution to help biopharma and medtech companies bring their Software as a Medical Device (SaMD) to market faster, according to BrightInsight CEO and Co-founder Dr. Kal Patel.
Some of the biggest legal stories of the year include patients attempting to mount a class action lawsuit against Mayo Clinic after an employee improperly viewed more than 1,600 health records and the Supreme Court hearing opening arguments in a case challenging the constitutionality of the ACA's individual mandate.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The pharmaceutical company will use Seqster’s system to speed up onboarding for clinical trials and to improve patient engagement.
Amwell raised $194 million in a series C funding round led by Allianz X and Takeda. The telehealth giant has seen a surge in visits during the Covid-19 pandemic.
According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
Nikkei Asian Review reported that the company would cover some or all the cost of the therapy, Alofisel, which won EMA approval last year, if it did not provide benefit. The UK's NICE has declined to recommend it, citing modest benefit in a clinical trial.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company secured $60 million in a Series A round from Third Rock and Takeda, plus a partnership with Takeda.
Me-too drugs and ill-defined AI are less interesting than unmet need and AI with supporting evidence.
Nearly a dozen companies were identified in a report as potentially attractive for buyouts by larger firms. Japanese companies could be big players.
In a new report, the Health Care Council of Chicago, an initiative of Matter and Leavitt Partners, outlined the current status of Chicago's healthcare ecosystem.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
A report from Rock Health on streamlining enterprise sales in digital health found that more than half of CEOs (54 percent) admitted to doing "very little" or just "moderate" research on the would-be customers they pitched. Cue facepalm.
Deals and acquisitions, filling in pipeline gaps, externalizing assets that are no longer a good fit. What really goes on when pharma companies restructure their R&D approach?
Washington University spin-out PvP Biologics has bypassed traditional seed financing, jumping straight into a development agreement with Takeda Pharmaceuticals to further its investigational therapy for celiac disease.
Takeda U.S.'s Vice President for External Partnerships, Nicole Mowad-Nassar talked about the company's collaboration with technology partners and health systems to advance digital health at Health 2.0 this week.
Virginia startup Gencia is developing a mitochondrial therapeutic that could prove an alternative to the widely prescribed steroid. It just entered a deal worth up to $500 million with Japanese pharma giant Takeda.